Effects of rituximab and hyaluronidase human injection: A Synthesis of Findings from 13 Studies

  1. Home
  2. Effects of rituximab and hyaluronidase human injection
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of rituximab and hyaluronidase human injection: A Synthesis of Findings from 13 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of rituximab and hyaluronidase human injection: A Synthesis of Findings from 13 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major Research Findings

Several studies have investigated the effects of rituximab and hyaluronidase human injection on different aspects of HIV infection and treatment. 12 explored the impact of darunavir/ritonavir and atazanavir/ritonavir on insulin sensitivity in HIV-infected individuals over 48 weeks. The study found that both regimens had comparable effects on metabolic parameters, suggesting that both may affect insulin sensitivity similarly. 7 focused on simplifying the treatment regimen for patients on tipranavir/ritonavir. It found that lowering the ritonavir dose from 200mg to 100mg resulted in positive outcomes for some patients, including reduced aminotransferases and cholesterol levels, although it also observed a decline in tipranavir levels. 8 investigated the effects of higher dose ritonavir on insulin sensitivity in healthy individuals without HIV. It concluded that higher dose ritonavir alone did not significantly alter peripheral insulin sensitivity. 6 examined the effects of various antiretroviral medications, including ritonavir-boosted protease inhibitors, on lipid levels in HIV patients. The study observed a range of lipid elevations depending on the specific drug combinations, highlighting the importance of considering individual lipid profiles and selecting appropriate medications. 5 compared the effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose metabolism, finding that atazanavir/ritonavir had significantly less impact on insulin sensitivity. 10 explored the use of lopinavir/ritonavir monotherapy for HIV maintenance. The study concluded that monotherapy was not effective in all cases and should not be considered as a standard strategy, particularly for patients with a low nadir CD4 cell count. It also highlighted the importance of monitoring HIV levels in different compartments like the central nervous system.

Benefits and Risks

Benefit Summary

Rituximab and hyaluronidase human injection can be effective in treating HIV infection, particularly when used in combination therapies. 12 suggests that both darunavir/ritonavir and atazanavir/ritonavir have comparable effects on metabolic parameters, suggesting potential benefits for managing HIV infection while minimizing metabolic complications. Additionally, 7 indicates that simplifying the treatment regimen, where feasible, can lead to positive outcomes for some patients, potentially improving their quality of life and reducing pill burden.

Risk Summary

There are potential risks associated with rituximab and hyaluronidase human injection. 6 highlights the possibility of lipid level elevations, especially when using ritonavir-boosted protease inhibitors, which could contribute to cardiovascular risks. 10 emphasizes that monotherapy approaches, particularly with lopinavir/ritonavir, may not be effective in all patients and should be cautiously considered, especially for individuals with a low nadir CD4 cell count.

Comparison Between Studies

Similarities Between Studies

The studies generally agree that ritonavir and other protease inhibitors can have significant effects on metabolic parameters like insulin sensitivity and lipid levels in HIV-infected individuals. They also highlight the importance of considering the specific drug combinations and patient characteristics to optimize treatment and minimize potential side effects.

Differences Between Studies

Different studies investigated various aspects of ritonavir and other protease inhibitors. 12 focused on the metabolic effects of specific protease inhibitor combinations, while 7 explored the potential benefits of simplifying treatment regimens. 8 examined the effects of high-dose ritonavir alone on insulin sensitivity in healthy individuals, providing valuable insights into the drug's impact outside the context of HIV infection. 6 analyzed the broader effects of various antiretroviral medications on lipid levels. 5 specifically compared the metabolic effects of two protease inhibitor combinations. 10 focused on the effectiveness of lopinavir/ritonavir monotherapy, highlighting potential limitations and the need for careful monitoring.

Consistency and Contradictions in Results

While the studies generally agree on the potential effects of ritonavir and other protease inhibitors on metabolic parameters, some inconsistencies exist. For example, 8 showed that high-dose ritonavir alone did not significantly alter peripheral insulin sensitivity, while 12 suggested that ritonavir combined with other protease inhibitors could affect insulin sensitivity. This highlights the complexity of the drug's effects and the need for further research to understand the full range of its impacts on different individuals. 10 found that lopinavir/ritonavir monotherapy was not effective in all cases, which contradicts the potential for simplified regimens suggested in 7 . This discrepancy emphasizes the importance of individual patient factors in determining the best treatment approach.

Considerations for Real-Life Application

When considering the use of rituximab and hyaluronidase human injection for HIV management, it is important to be aware of the potential benefits and risks. Carefully monitoring patient responses to treatment, including metabolic parameters like lipid levels and insulin sensitivity, is crucial. 6 suggests that choosing appropriate drug combinations based on individual lipid profiles can help minimize the risk of cardiovascular complications. 10 highlights the importance of avoiding monotherapy approaches for patients with low nadir CD4 cell counts.

Limitations of Current Research

The studies reviewed here have limitations. 10 involved a relatively small number of participants, which could limit the generalizability of its findings. Further research is needed to fully understand the long-term effects of different ritonavir-containing regimens, particularly in diverse populations and across various clinical contexts.

Future Directions for Research

Future research should focus on investigating the long-term effects of ritonavir and other protease inhibitors on insulin sensitivity, lipid levels, and other metabolic parameters. Studies should also explore the factors that influence individual responses to treatment, including patient characteristics, genetic predisposition, and lifestyle factors.

Conclusion

Rituximab and hyaluronidase human injection are valuable tools in the management of HIV infection. However, their use should be carefully considered, taking into account potential benefits and risks. Regular monitoring of patient responses, especially regarding metabolic parameters and potential side effects, is crucial. Further research is needed to fully understand the complex effects of these drugs and to optimize treatment approaches for diverse individuals.

Literature analysis of 13 papers
Positive Content
11
Neutral Content
0
Negative Content
2
Article Type
12
1
0
0
13
1.

Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir.

Author: KelleherA D, CarrA, ZaundersJ, CooperD A

HIV-1 infection treatment
Immune system improvement

Ritonavir, an HIV-1 protease inhibitor, significantly increased CD4 and CD8 lymphocyte counts and improved immune function in 21 patients.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

2.

Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects.

Author: HsuA, GrannemanG R, WittG, LockeC, DenissenJ, MollaA, ValdesJ, SmithJ, ErdmanK, LyonsN, NiuP, DecourtJ P, FourtillanJ B, GiraultJ, LeonardJ M

Increased triglyceride levels

Ritonavir, an HIV treatment, showed moderately dose-dependent pharmacokinetics with concentration-dependent autoinduction. Triglyceride levels increased with higher ritonavir doses. This data provides information about its absorption, elimination, and potential side effects.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

3.

The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin.

Author: CatoA, CavanaughJ, ShiH, HsuA, LeonardJ, GrannemanR

Increased rifabutin levels

Ritonavir significantly increases the plasma concentrations of rifabutin and its metabolite 25-O-desacetylrifabutin, suggesting that both drugs are metabolized by CYP3A.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

4.

Short-term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone.

Author: GreenblattDavid J, von MoltkeLisa L, HarmatzJerold S, FogelmanSteven M, ChenGengsheng, GrafJennifer A, MertzanisPolyxane, ByronSusan, CulmKerry E, GrandaBrian W, DailyJohanna P, ShaderRichard I

Drug interactions

Ritonavir significantly reduced apparent oral clearance of trazodone, prolonged elimination half-life, and increased peak plasma concentrations (mean +/- SE). Coadministration of trazodone with ritonavir increased sedation, fatigue, and performance impairment compared to trazodone plus placebo.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Language : English

6.

Effects of first-line use of nucleoside analogues, efavirenz, and ritonavir-boosted protease inhibitors on lipid levels.

Author: HillAndrew, SawyerWill, GazzardBrian

Lipid elevation

There is a wide range of lipid elevations during 48 weeks of first-line HAART, depending on the choice of antiretrovirals used.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.

Language : English

7.

The benefit of simplification from tipranavir/ritonavir 500/200 bid to 500/100 bid guided by therapeutic drug monitoring.

Author: MorelloJudit, Rodríguez-NovoaSonia, BlancoFrancisco, VispoEugenia, BarreiroPablo, Gonzalez-PardoGema, Jiménez-NácherInmaculada, González-LahozJuan, SorianoVincent

HIV suppression
Reduced aminotransferases
Reduced cholesterol
Reduced triglycerides
Pill burden
Side effects

Tipranavir is a potent protease inhibitor but has a high pill burden and frequent side effects. This study found that reducing the ritonavir dose in patients taking tipranavir/ritonavir resulted in decreased liver enzymes and cholesterol levels in some patients without affecting viral suppression.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

8.

Boosting dose ritonavir does not alter peripheral insulin sensitivity in healthy HIV-seronegative volunteers.

Author: TaylorSteven A, LeeGrace A, PaoVivian Y, AnthonypillaiJayaranjan, AweekaFrancesca T, SchwarzJean-Marc, MulliganKathleen, SchambelanMorris, GrunfeldCarl

Insulin resistance

Some HIV protease inhibitors (PIs), including full-dose ritonavir (800 mg) and ritonavir-boosted lopinavir, acutely induce insulin resistance in the absence of HIV infection. The effects of boosting dose ritonavir (100-200 mg) on glucose metabolism have not been described in the absence of another PI.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, U.S. Gov't, Non-P.H.S.Research funding provided by US government agencies other than the Public Health Service.

Language : English

9.

Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients.

Author: SquiresKathleen E, YoungBenjamin, DejesusEdwin, BellosNicholaos, MurphyDaniel, ZhaoHenry H, PatelLisa G, RossLisa L, WannamakerPaul G, ShaeferMark S,

HIV treatment
Reduced side effects

Treatment simplification strategies involving induction with a ritonavir (RTV)-boosted protease inhibitor regimen followed by simplification without RTV may offer sustained virologic suppression while minimizing long-term adverse effects associated with RTV.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

10.

Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir.

Author: GutmannChristine, CusiniAlexia, GünthardHuldrych F, FuxChristoph, HirschelBernard, DecosterdLaurent-Arthur, CavassiniMatthias, YerlySabine, VernazzaPietro L,

Reduced viral load
Treatment failure

Monotherapy with ritonavir-boosted lopinavir was not recommended as a standard strategy for HIV maintenance, especially in patients with a low nadir CD4 cell count. Viral failure was observed in patients with a low nadir CD4 cell count, and further research is needed to understand the role of the central nervous system in monotherapy failure.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

11.

Early lipid changes with atazanavir/ritonavir or darunavir/ritonavir.

Author: MartinezE, Gonzalez-CordonA, FerrerE, DomingoP, NegredoE, GutierrezF, PortillaJ, CurranA, PodzamczerD, MurillasJ, BernardinoJ I, SantosI, CartonJ A, PeraireJ, PichJ, PerezI, GatellJ M,

Lipid effects
Tolerability
Hyperbilirubinaemia

This study examines the lipid effects and overall tolerability of ritonavir-boosted atazanavir and darunavir compared to ritonavir-boosted lopinavir in patients with HIV infection.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

12.

Effects of once-daily darunavir/ritonavir versus atazanavir/ritonavir on insulin sensitivity in HIV-infected persons over 48 weeks: results of an exploratory substudy of METABOLIK, a phase 4, randomized trial.

Author: OvertonEdgar Turner, TebasPablo, CoateBruce, RyanRobert, PerniciaroAmy, DayaramYaswant K, De La RosaGuy, BaughBryan P

Darunavir with low-dose ritonavir (DRV/r) and atazanavir with low-dose ritonavir (ATV/r) are antiretroviral medications. This study assessed the effects of these agents on insulin sensitivity.

Clinical Trial, Phase IVPost-marketing surveillance. Monitors long-term safety/efficacy after approval.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

13.

Neurocognitive Function and Neuroimaging Markers in Virologically Suppressed HIV-positive Patients Randomized to Ritonavir-boosted Protease Inhibitor Monotherapy or Standard Combination ART: A Cross-sectional Substudy From the PIVOT Trial.

Author: Arenas-PintoAlejandro, StöhrWolfgang, JägerHans Rolf, HaddowLewis, ClarkeAmanda, JohnsonMargaret, ChenFabian, WinstonAlan, GodiClaudia, ThustSteffi, TrombinRita, CairnsJanet, SolankyBhavana S, GolayXavier, PatonNicholas I,

HIV treatment

This study assessed the neurocognitive function and brain imaging markers of patients on ritonavir-boosted protease inhibitor (PI) monotherapy versus standard antiretroviral therapy (ART). There was no difference in neurocognitive impairment between the two groups. However, symptomatic neurocognitive impairment was associated with higher global cortical atrophy scores.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.